Praxis Precision Medicines Inc (PRAX) Company Value to Net Income
High risks of clinical failures in the race for the neuropreparations market determine the fate of Praxis Precision Medicines (PRAX). The GURU.Markets system displays the company's price-to-earnings ratio, where the value -25.40 indicates the current figure. The business model relies on external molecule synthesis, and the financial condition is characterized by the planned depletion of capital reserves in the absence of operating revenue.
%20P%2FE%20Multiple&width=1200&height=400&colorIndex=0&v=mwhdatcg.m7-7dqbc3k&start=20220704&end=20261115&filename=GURU_Markets_-_PRAX_-_Praxis-Precision-Medicines_-_PE-Multiple "PRAX: praxismedicines.com P/E Multiple 07/04/2022 - 11/15/2026 | 👁️GURU.Markets👁️")
Analytical breakdowns for Praxis Precision Medicines
- stock price and consensus target price:
- market capitalization details:
- balance sheet net asset value indicators:
- debt and solvency information:
Total Debt to Capital Coefficient Praxis Precision Medicines|PRAX - Long-Term Debt to Equity|Short-Term Debt to Capital Coefficient Praxis Precision Medicines, Inc.|PRAX - Company Total Debt|Debt to Net Assets Ratio Praxis Medicines|PRAX - Company Long-Term Debt|Current Liabilities Praxis Precision Medicines|Intermediate Coverage Ratio praxismedicines.com
- net income and valuation ratios data:
PRAX - Net Profit|Expected Net Profit Praxis Precision Medicines|PRAX - P/E Multiple|Projected Price to Earnings Praxis Medicines|PRAX - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Praxis Medicines|PRAX - Profit before payment of interest, taxes and amortization|Net earnings per share for the last four quarters Praxis Precision Medicines|PRAX - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months praxismedicines.com|PRAX - Earnings per share growth in current year|Expected net earnings per share growth next year Praxis Precision Medicines
- issuer revenue and sales details:
General company analysis:Praxis Precision Medicines Inc - PRAX
For the biopharmaceutical ecosystem of Praxis Precision Medicines (PRAX), which is establishing a patent perimeter in the therapy of CNS diseases, the P/E ratio serves as a tool for assessing the return on investment through the ratio of market capitalization to net income. An analysis of the company's historical average P/E allows for the distinction between fundamental undervaluation and a value trap, determining the extent to which the current business value is justified by the quality of its operating cash flows.
Analysis of competing companies
Price to Earnings Ratio BIIB|P/E Multiple NBIX|Regencell (RGC) - Market Cap to Net Income Ratio|Price to Earnings Ratio axsome.com AXSM|P/E Multiple ACADIA Pharmaceuticals ACAD|XENE - Price to Earnings Ratio|Business Payback Period Viking Therapeutics Inc VKTX|Supernus Pharma (SUPN) - Price to Earnings Ratio|CPRX (Catalyst Pharmaceuticals) - Price to Earnings Ratio|DNLI (denalitherapeutics.com) - P/E Multiple|Price to Earnings Multiple HRMY (Harmony Biosciences Holdings, Inc.)|P/E Multiple BHVN|AMLX (Amylyx Pharmaceuticals Inc) - Company Value to Net Income|P/E Multiple TRVI (Trevi Pharma)|Anavex Corp - Price to Earnings Ratio|CBLL: Price to Earnings Ratio|Company Value to Net Income PRTA (prothena.com)|Alector, Inc. (ALEC) - Price to Earnings Ratio|Price to Earnings Multiple ANNX|Price to Earnings Ratio Omeros Corp.|Neurogene Therapeutics (NGNE) - Business Payback Period|P/E Multiple ACIU|VYGR (Voyager Therapeutics) - Company Value to Net Income|P/E Multiple NMRA (neumoratx.com)|SCLX: Price to Earnings Multiple|TVGN - Price to Earnings Ratio|Market Cap to Earnings Alpha Cognition Inc.|CGTX: P/E Multiple|inhibikase.com (IKT) - P/E Multiple|Price to Earnings Ratio Cassava Sciences Inc|ASRT - Market Cap to Net Income Ratio|Price to Earnings Ratio Coya (COYA)|P/E Multiple VistaGen Therapeutics Inc (VTGN)|Ovid Therapeutics Inc. - Price to Earnings Ratio|Business Payback Period Acumen Pharmaceuticals (ABOS)|CervoMed Corporation - P/E Multiple|Business Payback Period alteritytherapeutics.com ATHE|CLNN: P/E Multiple|Market Cap to Earnings PepGen Corp (PEPG)|Price to Earnings Ratio Jupiter Neurosciences, Inc.|RLMD: Company Value to Net Income|P/E Multiple ANVS|Price to Earnings Ratio Grace Tx GRCE|Price to Earnings Ratio Firefly Neuroscience, Inc AIFF|KLTO: Price to Earnings Multiple|NRSN - Price to Earnings Ratio|RVPH: Price to Earnings Ratio|MTVA (MetaVia Inc.) - Price to Earnings Ratio|NeurAxis Inc. (NRXS) - P/E Multiple|Price to Earnings Ratio Helius Medical|Passage Bio, Inc. - Market Cap to Net Income|Price to Earnings Ratio NEUP (Neuphoria)|NERV - Market Cap to Earnings|P/E Multiple ATHA (athira.com)|P/E Multiple Addex Therapeutics Ltd ADXN|Alzamend Neuro, Inc. - P/E Multiple|CYCN - P/E Multiple|PTIX (Protagenic Therapeutics, Inc.) - Price to Earnings Ratio|Market Cap to Earnings Pasithea (KTTA)|Price to Earnings Ratio Cortigent|Market Cap to Earnings Avenue Therapeutics Inc. ATXI|Price to Earnings Ratio brainstorm-cell.com (BCLI)|Price to Earnings Ratio Cara Therapeutics, Inc CARA|P/E Multiple CHRO (chromocell.com)|Company Value to Net Income ELYM|Intra-Cellular Therapies Inc. - P/E Multiple|Market Cap to Earnings Longboard Pharmaceuticals Inc|Marinus (MRNS) - Price to Earnings Ratio|NKGN - Business Payback Period|Price to Earnings Ratio NeuroBo Pharmaceuticals|SAGE: Company Value to Net Income|P/E Multiple SNPX|Trevena Inc. - Price to Earnings Multiple|Price to Earnings Ratio Vigil Neuroscience, Inc. VIGL|Anew Medical, Inc. - Price to Earnings Ratio|Cerevel Therapeutics - P/E Multiple
